Pandemic Perspectives: US FDA, NIH Tried To Be Flexible To Keep Rare Disease Trials Going
Both federal agencies extended grants to help investigators adapt to the changes mandated by the COVID-19 pandemic.
You may also be interested in...
The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.